CI Stock Price Today (July 2026) — The Cigna Group Analysis & Key Metrics 2026-07-17
The Cigna Group (CI) is trading at $281.45, down 0.83% today (as of July 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $340.50 (21.0% upside).
- Volatility remains elevated (29.97% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (4.60% YoY) alongside significant competitive pressures.
CI Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
The Cigna Group - Historical Price & Volume
Market Cap
Enterprise Value: $96.21B
P/E Ratio
Forward P/E: 8.24
Revenue Growth
Year over Year
Analyst Target
+21.0% upside potential
Key Investor Questions About CI
What investors need to know before buying
Based on current market data, CI presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 42.23)
- Fundamentals say: Caution warranted (high leverage concerns)
CI's growth trajectory depends on its ability to expand within the Healthcare Plans sector while managing margin pressures.
- Future growth will depend on performance in core Healthcare Plans operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for CI investors include debt exposure and competitive dynamics in the Healthcare Plans industry.
- $30.90B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Healthcare Plans.
52-Week Trading Range
Over the past year, CI stock traded between $239.51 and $338.89—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 29.97% annualized volatility and β=0.19, the stock exhibits low sensitivity to market moves—making CI suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Cigna Group (CI) Faces A Valuation Test, Is The Recent Pullback A Buying Opportunity?
Cigna Group (CI) continues to draw investor attention after recent share moves, with the stock last closing at US$281.45. The company’s mixed return profile over various periods is prompting closer scrutiny of its valuation and fundamentals. See our latest analysis for Cigna Group. Recent trading shows some cooling in momentum for Cigna Group, with the 1 day share price return slipping 0.83% and the 7 day return down 4.09%. The 5 year total shareholder return of 32.51% points to a steadier...
What A Patient Holder Is Really Paying For CVS Health Stock
The sticker price on CVS shares looks high, but the real question is what it costs on the earnings expected two years from now.
What's A Strong Quarter Worth When Elevance Health Is Ditching Its Own Markets?
The health insurer raised its forecast after a solid quarter, but investors focused on the one business so broken it’s forcing a strategic retreat.
Why UNH Stock Breakout Faltered After Massive Earnings Beat
UnitedHealth Group crushed Q2 earnings forecasts amid lower-than-expected benefit costs, sending the Dow Jones stock surging past a buy point on Thursday morning. Rival managed-care providers including Humana, Centene and Elevance Health got a sizable lift from the initial warm reception for UnitedHealth's earnings report. Results: UnitedHealth posted Q2 earnings per share of $6.38, up 56% from a weak year-earlier result and 30% ahead of $4.91 forecasts.
The Medicaid Problem That Swallowed an Earnings Beat
Elevance Health raised its profit forecast and the stock promptly fell. Here’s the one number that explains why investors headed for the exits.
The Medicaid Problem Weighing On Elevance Health Stock
The stock is priced for strength, but a deep and persistent drag from one of its largest divisions could challenge the optimistic narrative.
The Real Price of Admission for CVS Health Stock
The stock's current valuation looks steep, but for a patient holder, the price tag on future earnings tells a very different story.
FTC Reaches Settlement With CVS Health Over Insulin Prices
The Federal Trade Commission announced a settlement with CVS Health’s pharmacy benefit manager business on Tuesday, the agency’s second major agreement this year with drug industry middlemen. Pharmacy-benefit managers, or PBMs, play a key role in negotiating with drug companies and selecting which prescription drugs will be covered by an insurance plan. In litigation filed in 2024 during the Biden administration, the commission alleged that rebates and fees collected by major PBMs from drug manufacturers artificially inflated the price of insulin.
Stocks making big moves yesterday: RXO, Progyny, Cigna, GoodRx, and Domino's
Check out the companies making headlines yesterday:
Update: Market Chatter: DOJ Expands Antitrust Probe Into Claritev
(Updates with Claritev's response in the fourth paragraph.) The US Justice Department recently se
Frequently Asked Questions
Common investor questions about The Cigna Group
The Cigna Group (CI) is currently trading at $281.45. The RSI (14-day) is at 42.2, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $340.50 implies 21.0% upside from current levels. Volatility is moderate at 30.0% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for The Cigna Group (CI): The trailing P/E ratio is 11.93, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 8.24, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.83, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 1.76. Price-to-Sales is 0.27. Valuation should be compared to Healthcare Plans industry peers for context, as different sectors trade at different multiples.
Based on 24 analysts covering CI, the consensus price target is $340.50. This represents a 21.0% upside from the current price of $281.45. The range spans from a low target of $290.00 to a high target of $400.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, The Cigna Group (CI) pays a dividend with a current yield of approximately 2.22%. The annualized dividend rate is $6.09 per share. The payout ratio is 25.8%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-06-04T00:00:00.000Z.
Key risks for The Cigna Group (CI) investors include: 1. Moderate volatility (30.0% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Healthcare Plans sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is The Cigna Group's (CI) current debt and financial health profile: Total debt stands at $30.90B. The debt-to-equity ratio is 72.81, which is moderate and generally manageable for most companies. The current ratio is 0.82, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.66. The company holds $7.85B in cash and equivalents. Free cash flow is positive at $6.92B, providing a cushion for debt servicing and shareholder returns.